The historical rank and industry rank for Instituto Rosenbusch's ROE % or its related term are showing as below:
BUE:ROSE'
s ROE % Range Over the Past 10 Years
Min: -314.13 Med: -9.53 Max: 46.27
Current: -314.13
During the past 13 years, Instituto Rosenbusch's highest ROE % was 46.27%. The lowest was -314.13%. And the median was -9.53%.
BUE:ROSE's ROE % is ranked worse than 98.71% of 933
companies
in the Drug Manufacturers industry
Industry Median: 5.89
vs BUE:ROSE: -314.13
Instituto Rosenbusch (BUE:ROSE) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instituto Rosenbusch ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's ROE % distribution charts can be found below:
* The bar in red indicates where Instituto Rosenbusch's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.
Instituto Rosenbusch (BUE:ROSE) has a ROE % of 0.00% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Instituto Rosenbusch and its competitors. According to the industry distribution chart, Instituto Rosenbusch ranks #921 out of 933 companies in the Drug Manufacturers industry, placing it in the top 98.7%.
Is Instituto Rosenbusch's ROE % too high?
Instituto Rosenbusch's current ROE % is 0.00%. Based on the distribution chart, Instituto Rosenbusch ranks #921 out of 933 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Instituto Rosenbusch has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #921 out of 933 companies for ROE %. This places Instituto Rosenbusch in the lower half of its industry. The industry median ROE % is 5.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.89, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Instituto Rosenbusch and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS61.70, compared to a current price of ARS162.00 — trading 162.6% above its estimated fair value. The current ROE % is 0.00%. Instituto Rosenbusch's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current ROE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS162.00 is trading 162.6% above its estimated GF Value™ of ARS61.70.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
ROE %: 0.00%
GF Value™: ARS61.70 vs. price of ARS162.00 (162.6% above fair value)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
39GF Score
Get the complete analysis for BUE:ROSE
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
